Research & Development | Aerie Pharmaceuticals, Inc.
Durham-based Aerie Pharma sees positive study results for eye pressure drug | WRAL TechWire
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Rx Item-RHOPRESSA 0.02 % O/S 2.5 ML netarsudil mesylate DROPS BY AERIE PHARMA
Aerie Pharma appoints Richard Rubino as CFO
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Aerie Pharmaceuticals Inc - ZIP 27703, NAICS 423450
AERIE PHARMACEUTICALS, INC. - Aerie Pharmaceuticals, Inc. Trademark Registration
Aerie Pharma slips after announcing eye disease trial failed to meet primary endpoints | Seeking Alpha
Aerie Pharmaceuticals Inc (AERI): Are Hedge Funds Right About This Stock?
Aerie Pharmaceuticals | WRAL TechWire
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Investor Relations | Aerie Pharmaceuticals, Inc
Aerie Pharma (AERI) Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
Aerie Pharma to use DSM polymers to develop eye drug delivery tech
AeriePharma (@AeriePharma) | Twitter
Aerie Pharmaceuticals | Leading Ophthalmic Pharmaceuticals
Aerie Pharmaceuticals, Inc (AERI) July 7, 2021 Stock Price, Analysis & Forecast | List23: Latest U.S. News & Breaking World News
Our Eye Care Products | Aerie Pharmaceuticals, Inc.
Aerie Pharma Reports Mixed Bag On Phase 2 Dry Eye Trial
Aerie Pharmaceuticals, Inc.
